KIFAP3

Across TCGA pan-cancer cohorts, KIFAP3 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated KIFAP3 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher KIFAP3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated KIFAP3 expression acts as an unfavorable survival marker, although some lineages such as GBM and PDAC show a favorable association.

CCRCC, GBM, and PDAC are the cancer types where KIFAP3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.301	0.909	.002	30	view →
GBM	DFS	Median	All	0.890	0.615	<.001	20	view →
PDAC	OS	Tertile	II,III,IV	0.636	0.337	.001	15	view →
LSCC	OS	Median	III,IV	0.723	0.954	.009	10	view →
UCEC	DFS	Median	All	0.962	0.848	.025	6	view →
LUAD	OS	Quartile	II,III,IV	0.851	0.441	.026	4	view →
HNSC	DFS	Quartile	II,III,IV	1.000	0.908	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

KIFAP3–CCRCC (DFS)

Open the CCRCC breakdown →